Font Size: a A A

The Empirical Analysis Of The Bio-pharmaceutical Firm R&D Performance

Posted on:2016-06-03Degree:MasterType:Thesis
Country:ChinaCandidate:L YangFull Text:PDF
GTID:2309330479982667Subject:International business
Abstract/Summary:PDF Full Text Request
From 2005 to 2012, global bio-pharmaceutical industry market has improved 66.51% in 8 years; with its rapid growth rate,the R&D productivity of pharmaceutical firms has become an increasingly significant concern of industry, regulators, and policymakers. Although Chinese bio-pharmaceutical companies started their path slow, it has reached great progress, on the one hand, thanks to the government policy support and financial support, Chinese bio-pharmaceutical companies have been on the fast move, on the other hand, with the arrival of patent cliff,China has become a perfect place for international bio-pharmaceutical companies to undertake R & D outsourcing, technology spillover effect of China’s technological level of developed countries makes bio-pharmaceutical companies gradually increase. Bio-pharmaceutical is a technology-intensive industry, bio-pharmaceutical R & D investment has drawn high attention of business and government, with the hope that R & D spending can enhance the company’s long-term competitiveness, research and development enables companies to develop new products and enhance aspects of the work efficiency and enhance competitive advantage, improve business performance and value of their own, but bio-pharmaceutical R & D performance have been questioned by some scholars, for example, after examining 22 major US pharmaceutical companies’ 10 years of data, the scholar found out that the analysis and performance of R & D investment is a negative relationship; This article based on 34 listing companies in a row from 2009 to 2014 and make empirical analysis about the corporate R & D investment in the bio-pharmaceutical industry, besides the article divided the company into two kinds of scales, and view the relationship between the factors of R & D investment and enterprise development and performance separately. This article has an overall view of company scale and R & D investment performance’s relationship and draws a conclusion on the advice of the development of middle-scale bio-pharmaceutical companies.
Keywords/Search Tags:bio-pharmaceutical, enterprise’s scale, performance
PDF Full Text Request
Related items